Research programme: Huntington's disease gene therapy - Regeneron Pharmaceuticals

Drug Profile

Research programme: Huntington's disease gene therapy - Regeneron Pharmaceuticals

Alternative Names: AdBDNF/Noggin; Huntington's disease gene therapy

Latest Information Update: 02 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cornell University; Regeneron Pharmaceuticals; University of Rochester
  • Developer Regeneron Pharmaceuticals
  • Class Gene therapies
  • Mechanism of Action Brain-derived neurotrophic factor expression stimulants; Gene transference; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Huntington's disease

Most Recent Events

  • 21 Oct 2009 Pharmacodynamics data from a preclinical trial in Huntington's disease presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
  • 07 Dec 2005 Data presented at the 35th Annual Meeting of the Society for Neuroscience (SfN-2005) have been added to the Parkinson's Disease and Movement Disorders pharmacodynamics section
  • 10 Jun 2005 Preclinical trials in Huntington's disease in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top